1-(carboxymethylthio)tetradecane has been researched along with cardiovascular agents in 1 studies
| Studies (1-(carboxymethylthio)tetradecane) | Trials (1-(carboxymethylthio)tetradecane) | Recent Studies (post-2010) (1-(carboxymethylthio)tetradecane) | Studies (cardiovascular agents) | Trials (cardiovascular agents) | Recent Studies (post-2010) (cardiovascular agents) |
|---|---|---|---|---|---|
| 143 | 5 | 32 | 17,645 | 1,480 | 6,891 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aasum, E; Berge, RK; Clarke, K; Hafstad, AD; Hagve, M; Khalid, AM; Larsen, TS; Lund, T; Severson, DL | 1 |
1 other study(ies) available for 1-(carboxymethylthio)tetradecane and cardiovascular agents
| Article | Year |
|---|---|
Cardiac peroxisome proliferator-activated receptor-alpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss.
Topics: Administration, Oral; Animals; Blood Glucose; Cardiovascular Agents; Disease Models, Animal; Energy Metabolism; Fatty Acids; Gene Expression Regulation; Liver; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Myocardial Contraction; Myocardial Ischemia; Myocardium; Oxidation-Reduction; Oxygen Consumption; PPAR alpha; Recovery of Function; RNA, Messenger; Sulfides; Triglycerides; Ventricular Function | 2009 |